For patients switched to the Victoza 1.8 milligram group, mean A1C decreased from 7.2% at week 26 to 6.9% at week 40 (-0.32 +/-0.043%).  A greater percentage of patients reached their A1C targets after switching from exenatide to Victoza (42.5% vs 57.9%).  Switched patients also experienced further reductions in fasting plasma glucose (FPG) (0.9 +/-0.16 mmol/L), bodyweight (-1.98 +/-0.33 lbs), and systolic blood pressure (SBP) (-3.8 +/-0.84 mmHg).  In those continuing Victoza, reductions in FPG (-0.2 +/-0.11 mmol/L), bodyweight (-0.88 +/-0.33 lbs) and SBP (-2.2 +/-0.88 mmHg) occurred.

Similar numbers of patients reported adverse events in the extension.  The most common adverse events reported were diarrhea and nausea.

SOURCE Novo Nordisk